Abstracts tagged "inflammatory bowel disease (IBD)"

Abstract Number: 1831 • 2018 ACR/ARHP Annual Meeting
Intestinal Inflammatory Regulation in Murine and Human Spondyloarthropathy Requires High-Affinity T Cell Receptor-Zeta Chain-Associated Protein (ZAP)70-Mediated Runt-Related Transcription Factor (Runx)3 Activity
Zaied Ahmed Bhuyan¹, M. Arifur Rahman², Muralidhara Maradana¹, Ahmed Mehdi³, Giuliana Guggino⁴, Paul Leo⁵, Linda Rehaume¹, Matthew Brown⁵, Francesco Ciccia⁴ and Ranjeny Thomas¹, ¹The University of Queensland Diamantina Institute, Brisbane, Australia, ²Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ³Diamantina Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Rheumatology Unit, University of Palermo, Palermo, Italy, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia
Background/Purpose: Loss of function RUNX3 variants are associated with ankylosing spondylitis (AS) risk but the mechanism is unknown. Disturbances in immune regulation, intestinal microbial dysbiosis…
Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Mark C. Genovese¹, Jean-Frederic Colombel², Amanda M. Gellett³, Wen Xu³ and Dana Hardin³, ¹Department of Medicine, Stanford University, Palo Alto, CA, ²Department of Gastroenterology, The Mount Sinai Hospital, New York, NY, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…
Abstract Number: 1223 • 2017 ACR/ARHP Annual Meeting
Inflammatory Bowel Diseases and the Risks of Fracture and Low Mineral Density: Review of the Literature and Meta-Analysis of Observational Cohorts
Paulina Szafors¹, Thomas Barnetche², Cédric Lukas³, Jacques Morel⁴, Cécile Gaujoux-Viala^5,6, Bernard Combe⁷ and Hélène Che⁸, ¹Department of Rheumatology, Lapeyronie Hospital and University of Montpellier, Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁵Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁶EA 2415, Montpellier University, Nîmes, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁸Rheumatology, University and Hospital Lapeyronie, University of Montpellier, France
Background/Purpose: Inflammatory bowel diseases (IBD), such as Crohn disease (CD) and ulcerative colitis (UC), are associated with a decreased bone mineral density caused by chronic…
Abstract Number: 1576 • 2017 ACR/ARHP Annual Meeting
IL-23 Promotes Fecal Microbiota Dysbiosis Associated with Susceptibility to Spondyloarthritis and Ileitis in ZAP-70 Mutant SKG Mice
Linda Rehaume¹, Nicholas Matigian¹, Kate Ormerod², Alicia Kang¹, Richard Linedale¹, Olga Zbarskaya¹, Kristine Kikly³, Joshua Daly², Nancy Lachner², Philip Hugenholtz², Mark Morrison¹, Kim-Anh Lê Cao⁴ and Ranjeny Thomas¹, ¹The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ²Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia, ³Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, ⁴School of Mathematics and Statistics, Centre for Systems Genomics, The University of Melbourne, Melbourne, Australia
Background/Purpose: Identification of disease-associated or protective bacteria may elucidate new biomarkers or probiotic supplements for people suffering from SpA, or for people at-risk of disease…
Abstract Number: 1915 • 2017 ACR/ARHP Annual Meeting
Gut-Derived TNF As Risk Factor for the Development of Sacroiliac Inflammation
Karlijn Debusschere¹, Heleen Cypers², Peggy Jacques³, Filip van Den Bosch⁴, Thomas Renson⁵, Don Souza⁶, Martha Brown⁶, Gerald Nabozny⁷, Devin Dove⁶, Alexander Klimowicz⁸ and Dirk Elewaut⁹, ¹Ghent University - VIB, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴Rheumatology, Ghent University Hospital, Gent, Belgium, ⁵Rheumatology, Ghent University Hospital, GENT, Belgium, ⁶Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁸Department of Immunology and respiratory discovery research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁹VIB Inflammation Research Center, University of Ghent, Ghent, Belgium
Background/Purpose: An intruiging link exists between gut and joint inflammation in spondyloarthritis (SpA). About 50% of patients has subclinical (eg. microscopic) gut inflammation, which represents…
Abstract Number: 116 • 2017 Pediatric Rheumatology Symposium
Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
Kathryn Phillippi¹, Thomas Sferra², Nora Singer³ and Elizabeth Brooks⁴, ¹Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, ²Pediatric Gastroenterology, Rainbow Babies and Children's Hospital/Case Medical Center, Cleveland, OH, ³MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio, Cleveland, OH, ⁴Division of Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, Cleveland, OH
Background/Purpose: Inflammatory bowel disease (IBD) is associated with extra-intestinal manifestations, the most common of which is arthralgia/arthritis. 4.1- 15% of patients with inflammatory bowel disease…
Abstract Number: 92 • 2016 ACR/ARHP Annual Meeting
Is Patient Support Program (PSP) Participation Associated with Longer Persistence and Greater Adherence Among New Users of Adalimumab?
Einav Srulovici^1,2, Vishvas Garg³, Adi Ghilai², Becca Feldman², Moshe Hoshen², Ran Balicer², Martha Skup⁴ and Maya Leventer-Roberts², ¹School of Nursing, University of Haifa, Haifa, Israel, ²Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: In Israel, patients treated with adalimumab (ADA) can enroll in a patient support program (PSP) provided by AbbVie, which includes a home visit by…
Abstract Number: 693 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis
Maren C. Karreman^1,2, Jolanda J. Luime³, Johanna M.W. Hazes² and Angelique E.A.M. Weel¹, ¹Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Inflammatory Bowel Disease (IBD) is a chronic disease that affects up to 0.5% of the population, comprising both Crohn’s Disease (CD) and ulcerative colitis…
Abstract Number: 2405 • 2016 ACR/ARHP Annual Meeting
Musculoskeletal Manifestations As Presenting Symptoms of Inflammatory Bowel Disease in Children and Adolescents
Rachel Levy¹, Gil Amarilyo^2,3, Jacob Amir⁴, Rotem Tal^2,3, Amit Assa^3,5, Firas Rinawi⁵ and Liora Harel^2,3, ¹The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel, ²Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ³Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, Tel Aviv, Israel, ⁴Mayanei Hayeshua Medical Center, Bnei Brak, Israel, ⁵Institute of Gastroenterology Hepatology and Liver diseases, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel
Background/Purpose: Extra intestinal manifestations occur in 40-50% of patients with inflammatory bowel disease (IBD), with musculoskeletal involvement in 25%. Data regarding musculoskeletal manifestations in…
Abstract Number: 2694 • 2016 ACR/ARHP Annual Meeting
Treatment of ZAP-70 Mutant SKG Mice with Anti-IL-23 Antibody Alters Fecal Microbiota Composition and Prevents Outgrowth of Bacteria Associated with Susceptibility to Spondyloarthritis and Ileitis
Linda Rehaume¹, Nicholas Matigian¹, Alicia Kang¹, Olga Zbarskaya¹, Kristine Kikly², Nancy Lachner³, Joshua Daly³, Philip Hugenholtz³, Mark Morrison¹, Kim-Anh Lê Cao⁴ and Ranjeny Thomas¹, ¹Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ²Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, ³The University of Queensland, Australian Centre for Ecogenomics, Brisbane, Australia, ⁴Translational Research Instiute, The University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: Identification of disease-associated or protective bacteria may elucidate new biomarkers or probiotic supplements for people suffering from spondyloarthritis (SpA), or for people at-risk of…
Abstract Number: 2710 • 2016 ACR/ARHP Annual Meeting
Bacterial Dysbiosis Associates with Functional Intraepithelial Lymphocyte Changes in Inflammatory Bowel Disease and Spondyloarthritis
Neha Ohri^1,2,3, Mark Gerich^3,4, Blair Fennimore^3,5, Diana Ir⁶, Charles Robertson⁶, Daniel Frank⁶, Liron Caplan⁷, Brandie Wagner⁸ and Kristine Kuhn^9,10, ¹Division of Rheumatology, Mount Sinai West, New York City, NY, ²Division of Rheumatology, University of Colorado, Aurora, CO, ³Mucosal Inflammation Program, University of Colorado, Aurora, CO, ⁴Division of Gastroenterology, University of Colorado, Aurora, CO, ⁵Department of Gastroenterology, University of Colorado, Aurora, CO, ⁶Division of Infectious Disease, University of Colorado, Aurora, CO, ⁷Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ⁸Department of Biostatistics and Informatics, University of Colorado, Aurora, CO, ⁹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹⁰Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: The microbiome is hypothesized to influence human health and disease. Changes in resident bacteria, termed dysbiosis, occur in spondyloarthritis (SpA) and inflammatory bowel disease…
Abstract Number: 3164 • 2016 ACR/ARHP Annual Meeting
Spondyloarthritis Pathogenesis Involves Interplay Between Gut Microbiota and Genetic Background
Tejpal Gill¹, Mark Asquith², Stephen Brooks³, James T. Rosenbaum² and Robert A. Colbert¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Oregon Health & Science University, Portland, OR, ³NIAMS/NIH, Bethesda, MD
Background/Purpose: HLA-B27 and human b2m expression in rats induces a spontaneous inflammatory disease resembling human spondyloarthritis (SpA). While aspects of rat SpA have been studied…
Abstract Number: 2827 • 2015 ACR/ARHP Annual Meeting
Analysis of HLA-B27 Transgenic Rats Reveals Specific Gut Transcriptome and Microbiome Signatures Associated with Inflammation
Tejpal Gill¹, Mark Asquith², Stephen Brooks¹, James T. Rosenbaum³ and Robert A. Colbert⁴, ¹NIAMS/NIH, Bethesda, MD, ²OHSU, Portland, OR, ³Devers Eye Institute, Legacy Hospital system, Portland, OR, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: HLA-B27 and human beta 2-microglobulin expression in rats (transgenic; TG) induces a spontaneous inflammatory disease resembling human spondyloarthritis (SpA) with associated gastrointestinal inflammation. While…
Abstract Number: 2828 • 2015 ACR/ARHP Annual Meeting
Profiling Immunogenic Bacteria within the Microbiota of ZAP-70 Mutant SKG Mice Associated with Spondyloarthritis and Ileitis Using IgA-SEQ
Linda Rehaume¹, Alicia Kang¹, Olga Zbarskaya¹, Jane Mullaney¹, Matthew Kim¹, Paraic O Cuiv¹, Nicola Angel², Philip Hugenholtz², Mark Morrison¹ and Ranjeny Thomas¹, ¹Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ²Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia
Background/Purpose: IgA production is the main barrier mechanism of mucosal surfaces. High affinity IgA is generated through T cell-dependent mechanisms and preferentially binds to invasive…
Abstract Number: 37 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors
Luis Rodriguez-Rodriguez^1,2, Pedro P Perrotti³, Adrìa Aterido³, Jesús Tornero⁴, Carlos Ferrandiz⁵, Juan D. Cañete⁶, Antonio Fernandez-Nebro⁷, Javier P Gisbert⁸, Eugeni Domènech^9,10, María López-Lasanta³, Sara Marsal³, Benjamín Fernández-Gutiérrez^1,11 and IMID Consortium, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ³Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁴Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ⁵Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁷Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ⁸Gastroenterology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁹Gastroenterology & Hepatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰CIBERehd, Madrid, Spain, ¹¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose : Our aim was 1) to analyze the association between demographic and traditional cardiovascular risk factors (CVRF) and cardiovascular disease (CVD) in subjects affected…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].